When competing risks are present, the appropriate estimate of the failure probabilities is the cumulative incidence. stcompet creates new variables containing the estimate of this function, its standard error, and ln(– ln) transformed confidence bounds. Two examples are presented to illustrate the use of the new command and some key features of the cumulative incidence.
ByarD. P., and GreenS.B.1980. Prognostic variables for survival in a randomized comparison of treatments for prostate cancers. Bulletin du Cancer67: 477–490.
2.
ChoudhuryJ. B.2002. Nonparametric confidence interval estimation for competing risks analysis: application to contraceptive data. Statistics in Medicine21: 1129–1140.
3.
DinseG. E., and LarsonM.G.1986. A note on semi-Markov models for partially censored data. Biometrika73: 379–386.
4.
GaynorJ. J., FenerF. J., TanC. C., WuD. H., LittleC. R., StrausD. J., Clark-sonB. D., and BrennanM.F.1993. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. Journal of the American Statistical Association18: 400–409.
5.
GooleyT. A., LeisenringW., CrowleyJ., and StorerB.E.1999. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine18: 695–706.
6.
GrayR. J.1988. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics16: 1141–1154.
7.
KalbfleischJ. D., and PrenticeR.L.2002. The Statistical Analysis of Failure Time Data.2d ed. New York: John Wiley & Sons.
8.
KayR.1986. Treatment effects in competing-risks analysis of prostate cancer data. Biometrics42: 203–211.
9.
LunnM., and McNeilD.1995. Applying Cox regression to competing risks. Biometrics51: 524–532.
10.
MarubiniE., and ValsecchiM.G.1995. Analysing Survival Data from Clinical Trials and Observational Studies.Chichester, UK: John Wiley & Sons.
